Skip to main content

Table 4 Clinical assessments in each group at different time intervals (n = 54)

From: Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial

  Preop 2 week 6 week 3 months 6 months 1 year 2 years
N mean ± SD N mean ± SD N mean ± SD N mean ± SD N mean ± SD N mean ± SD N mean ± SD
Harris hip score
 Group ZA 27 60.31 ± 10.49 27 56.23 ± 14.06 27 70.96 ± 13.03a 27 77.93 ± 10.63a 27 83.60 ± 7.52a 27 86.34 ± 7.08a 27 90.18 ± 2.11a
 Group N/S 27 60.88 ± 11.63 27 58.80 ± 10.13 27 71.08 ± 12.26a 27 79.89 ± 9.42a 27 81.50 ± 9.87a 27 85.16 ± 7.28a 27 87.67 ± 5.44a
SF-12(PCS)
 Group ZA 27 27.53 ± 10.13 27 18.96 ± 7.48a 27 28.23 ± 11.35 27 40.01 ± 13.54a 27 48.09 ± 6.95a 27 51.29 ± 4.45a 27 53.69 ± 3.79a
 Group N/S 27 29.16 ± 11.31 27 21.37 ± 8.34a 27 27.79 ± 11.99 27 42.12 ± 10.61a 27 48.96 ± 7.90a 27 50.53 ± 6.95a 27 52.50 ± 4.16a
SF-12(MCS)
 Group ZA 27 57.65 ± 12.57 27 60.87 ± 9.51 27 59.23 ± 10.59 27 60.3 ± 6.86 27 58.85 ± 4.95 27 58.49 ± 4.07 27 58.61 ± 5.98
 Group N/S 27 59.17 ± 11.99 27 60.08 ± 7.29 27 63.72 ± 3.84 27 59.9 ± 4.77 27 55.97 ± 8.34 27 56.96 ± 7.20 27 59.01 ± 4.05
UCLA activity score
 Group ZA 27 3.96 ± 1.16 27 2.56 ± 0.80a 27 3.41 ± 0.97a 27 4.22 ± 0.93 27 4.63 ± 1.15 27 5.74 ± 1.06a 27 7.00 ± 0.90a
 Group N/S 27 4.33 ± 1.59 27 2.56 ± 0.70a 27 3.44 ± 0.97a 27 4.52 ± 0.94 27 4.70 ± 0.95 27 5.52 ± 1.19a 27 6.50 ± 0.74a
  1. Statistically significant difference between ZA and control groups
  2. asignificant difference between each time point and baseline
  3. SD Standard deviation, ZA zoledronic acid, SF short form, PCS physical component summary, MCS mental component summary, N/S normal saline